Đang chuẩn bị liên kết để tải về tài liệu:
Chapter 105. Malignancies of Lymphoid Cells (Part 10)

Table 105-9 International Prognostic Index for NHL Five clinical risk factors: Age ≥60 years Serum lactate dehydrogenase levels elevated Performance status ≥2 (ECOG) or ≤70 (Karnofsky) Ann Arbor stage III or IV 1 site of extranodal involvement Patients are assigned a number for each risk factor they have Patients are grouped differently based upon the type of lymphoma For diffuse large B cell lymphoma: 0, 1 factor = low risk: 73% 35% of cases; 5-year survival, 2 factors = low-intermediate risk: 51% 27% of cases; 5-year survival, 3 factors = high-intermediate risk: 43% 22% of cases; 5-year survival, 4, 5 factors = high risk: 26% 16% of cases; 5-year survival, For diffuse large B cell lymphoma treated. | Chapter 105. Malignancies of Lymphoid Cells Part 10 Table 105-9 International Prognostic Index for NHL Five clinical risk factors Age 60 years Serum lactate dehydrogenase levels elevated Performance status 2 ECOG or 70 Karnofsky Ann Arbor stage III or IV 1 site of extranodal involvement Patients are assigned a number for each risk factor they have Patients are grouped differently based upon the type of lymphoma For diffuse large B cell lymphoma 0 1 factor low risk 35 of cases 5-year survival 73 2 factors low-intermediate risk 27 of cases 5-year survival 51 3 factors high-intermediate risk 22 of cases 5-year survival 43 4 5 factors high risk 16 of cases 5-year survival 26 For diffuse large B cell lymphoma treated with R-CHOP 0 factor very good 10 of cases 5-year survival 94 1 2 factors good 45 of cases 5-year survival 79 3 4 5 factors poor 45 of cases 5-year survival 55 Figure .